OBJECTIVE
To study the MiniMed Advanced Hybrid Closed-Loop (AHCL) system, which includes an algorithm with individualized basal target set points, automated correction bolus function, and improved Auto Mode stability.
RESEARCH DESIGN AND METHODS
This dual-center, randomized, open-label, two-sequence crossover study in automated-insulin-delivery–naive participants with type 1 diabetes (aged 7–80 years) compared AHCL to sensor-augmented pump therapy with predictive low glucose management (SAP + PLGM). Each study phase was 4 weeks, preceded by a 2- to 4-week run-in and separated by a 2-week washout.
RESULTS
The study was completed by 59 of 60 people (mean age 23.3 ± 14.4 years). Time in target range (TIR) 3.9–10 mmol/L (70–180 mg/dL) favored AHCL over SAP + PLGM (70.4 ± 8.1% vs. 57.9 ± 11.7%) by 12.5 ± 8.5% (P < 0.001), with greater improvement overnight (18.8 ± 12.9%, P < 0.001). All age-groups (children [7–13 years], adolescents [14–21 years], and adults [>22 years]) demonstrated improvement, with adolescents showing the largest improvement (14.4 ± 8.4%). Mean sensor glucose (SG) at run-in was 9.3 ± 0.9 mmol/L (167 ± 16.2 mg/dL) and improved with AHCL (8.5 ± 0.7 mmol/L [153 ± 12.6 mg/dL], P < 0.001), but deteriorated during PLGM (9.5 ± 1.1 mmol/L [17 ± 19.8 mg/dL], P < 0.001). TIR was optimal when the algorithm set point was 5.6 mmol/L (100 mg/dL) compared with 6.7 mmol/L (120 mg/dL), 72.0 ± 7.9% vs. 64.6 ± 6.9%, respectively, with no additional hypoglycemia. Auto Mode was active 96.4 ± 4.0% of the time. The percentage of hypoglycemia at baseline (<3.9 mmol/L [70 mg/dL] and ≤3.0 mmol/L [54 mg/dL]) was 3.1 ± 2.1% and 0.5 ± 0.6%, respectively. During AHCL, the percentage time at <3.9 mmol/L (70 mg/dL) improved to 2.1 ± 1.4% (P = 0.034) and was statistically but not clinically reduced for ≤3.0 mmol/L (54 mg/dL) (0.5 ± 0.5%; P = 0.025). There was one episode of mild diabetic ketoacidosis attributed to an infusion set failure in combination with an intercurrent illness, which occurred during the SAP + PLGM arm.
CONCLUSIONS
AHCL with automated correction bolus demonstrated significant improvement in glucose control compared with SAP + PLGM. A lower algorithm SG set point during AHCL resulted in greater TIR, with no increase in hypoglycemia.
Objective:<br><p>
To study the MiniMed™ Advanced Hybrid Closed-Loop system (AHCL) which includes
an algorithm with individualised basal target set points, automated correction
bolus function, and improved Auto Mode stability.<br>
Research design and Methods:</p>
<p>This dual-centre, randomized, open-label, two-sequence
cross-over study in automated insulin delivery naïve participants with type 1
diabetes (aged 7-80yrs), compared AHCL to Sensor Augmented Pump therapy with
Predictive Low Glucose Management (SAP+PLGM). Each
study phase was 4 weeks, preceded by a 2-4 week run-in, and separated by 2-week
washout.</p>
<p><a>Results:<b> </b><br>
59/60 people completed the study (mean age 23.3±14.4yrs). Time in target range
(TIR) 3.9-10mmol/L (70-180 mg/dL) favoured AHCL over SAP+PLGM (</a>70.4±8.1 vs 57.9±11.7) by
12.5±8.5% (p<0.001), with greater improvement overnight (18.8±12.9%,
p<0.001). All age groups (children (7 – 13 years), adolescents (14 – 21
years), and adults (>22 years) demonstrated improvement, with adolescents
showing the largest improvement (14.4±8.4%). Mean sensor glucose (SG) at run in
was 9.3±0.9 mmol/L (167±16.2mg/dL) and improved with AHCL (8.5±0.7mmol/L (153±12.6mg/dL)
(p < 0.001)), but deteriorated during PLGM (9.5±1.1mmol/L (17±19.8mg/dL),
(p<0.001)).. TIR was optimal when the algorithm set point was 5.6 mmol/L
(100 mg/dL) compared to 6.7 mmol/L (120 mg/dL), 72.0±7.9% vs 64.6±6.9%
respectively with no additional hypoglycemia. Auto Mode was active 96.4±4.0% of
the time. <a>The percentage of hypoglycemia at
baseline (<3.9mmol/L (70mg/dl) and </a> £
3.0mmol/L(54mg/dl)) was 3.1±2.1% and 0.5±0.6%
respectively. During AHCL percentage time <3.9mmol/L (70mg/dl) improved to 2.1±1.4% (p=0.034) (70mg/dl), and was
statistically but not clinically reduced for £ 3.0mmol/L(54mg/dl) (0.5±0.5%, p = 0.025) There
was one episode of mild diabetic ketoacidosis attributed to an infusion set
failure in combination with an intercurrent illness, which occurred during the
SAP+PLGM arm.</p>
<p>Conclusions</p>
<p>AHCL with automated correction bolus demonstrated significant
improvement in glucose control compared to SAP+PLGM. A lower algorithm sensor
glucose set point during AHCL resulted in greater TIR, with no increase in
hypoglycemia.</p>
Background: The Medtronic Minimed® Advanced Hybrid Closed-Loop system (AHCL) includes an individualised algorithm with optional set points, automated correction bolus, and improved SmartGuard™ Auto Mode stability.
Methods: This dual-centre, randomized, open-label, two-sequence cross-over study in automated insulin delivery naïve participants (aged 7-80yrs), compared AHCL to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP+PLGM). Each study phase was 4 weeks, preceded by a 2-4 week run-in, and separated by 2-week washout.
Results: 59/60 people completed the study (mean age 23.3±14.4yrs). Overall time in target range (TIR) (70-180mg/dL) favoured AHCL over SAP+PLGM by 12.5±8.5% (p<0.001), with greater improvement overnight (15.7±12.0%, p<0.001) (Table 1). This was primarily due to reduction in hyperglycemia (-12.1±9.0% time spent >180mg/dL). Mean SG improved in AHCL by 10.0±7.4mg/dL (p<0.001). For each 1% lower baseline TIR, there was a 0.5% greater TIR improvement with AHCL (p<0.001). Auto Mode was active for 95.3±3.6% of the time.
Conclusion: AHCL with automated correction bolus showed significant improvement in glucose control compared to PLGM, in a population with a younger mean age reflecting a challenging demographic.
Disclosure
O. Collyns: None. R. Meier: None. Z. Betts: None. D. Chan: None. C. Frampton: None. C.M. Frewen: None. B. Grosman: Employee; Self; Medtronic. N. Hewapathirana: Other Relationship; Self; Sanofi. S. Jones: None. N. Kurtz: Employee; Self; Medtronic. A. Roy: Employee; Self; Medtronic. J. Shin: Employee; Self; Medtronic. R. Vigersky: Employee; Self; Medtronic. B.J. Wheeler: Research Support; Self; Medtronic. M. de Bock: None.
OBJECTIVE
To evaluate glycemic outcomes in youth (aged 13–25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL) therapy.
RESEARCH DESIGN AND METHODS
This prospective, 3-month, single-arm, dual-center study enrolled 20 participants, and all completed the study.
RESULTS
HbA1c decreased from 10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) at baseline to 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol), and time spent in target range 70–180 mg/dL (3.9–10.0 mmol/L) increased from 27.6 ± 13.2% at baseline to 66.5 ± 9.8% after 3 months of AHCL. Two episodes of diabetic ketoacidosis attributed to infusion set failure occurred.
CONCLUSIONS
AHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.